Mitsubishi UFJ Trust & Banking Corp Has $50.33 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mitsubishi UFJ Trust & Banking Corp cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 70,648 shares of the biopharmaceutical company’s stock after selling 5,676 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Regeneron Pharmaceuticals were worth $50,325,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $634.14 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $633.10 and a fifty-two week high of $1,211.20. The firm has a 50-day moving average of $687.18 and a 200 day moving average of $806.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market cap of $69.33 billion, a P/E ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.